Press Release Archives - IRIS CAPITAL INVESTMENT

24 Jan 25

Median Technologies Secures up to €10 million equity line completed with IRIS to enable 2025 EIB loan

Sophia Antipolis, France – jan 24, 2025 – Median Technologies a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnostics, and a globally leading provider of AI analyses and imaging services for oncology drug developers announces up to €10…

17 Dec 24

THERANEXUS AND EXELTIS (INSUD PHARMA) ANNOUNCE AN AGREEMENT LICENSE FOR THE MARKETING OF THERANEXUS TX01 IN THE TREATMENT OF TWO RARE NEUROLOGICAL DISEASES

Lyon, France, dec 17, 2024 – Theranexus, an innovative biopharmaceutical company specializing in the treatment of rare neurological diseases, and Exeltis, a global pharmaceutical company of the Insud Pharma group, announce the signing of a licensing and distribution agreement for the commercialization of Theranexus’ TX01, a new formulation of a…

16 Oct 24

Establishment of a renewable equity financing line of a maximum amount of €2 million to support the ramp-up of the Revin industrial site

Alfortville, France, oct 16, 2024 – CIBOX, French expert in electric micro-mobility, announces the establishment of financing for a maximum total amount of 2 million euros (renewable under conditions up to a maximum of 2 million additional euros) under the terms of ‘a contract for the issue and subscription of…

30 Sep 24

Poxel Announces Agreement with OrbiMed to Monetize a portion of TWYMEEG Royalties for USD 50 million

Lyon, France, sep 30, 2024 – Poxel Announces Agreement with OrbiMed to Monetize a portion of TWYMEEG® Royalties for USD 50 million DOWNLOAD Poxel press release

30 Sep 24

TheraVet announces a strategic transformation project aimed at creating a leader in human idiopathic pulmonary fibrosis

Gosselies, Belgium, Sep 30, 2024 –TheraVet today announces a strategic transformation project with H4Orphan aimed at creating a leader in idiopathic pulmonary fibrosis and accelerating the development of its multi-target drug candidate. DOWNLOAD Theravet press release

07 Aug 24

Sumitomo Pharma and Poxel AnnounceTopline Results from Post-MarketingClinical Study on TWYMEEG® for the Treatment of Type 2 Diabetes in Japan

Osaka, Japan & Lyon, France, aug 07, 2024 – Sumitomo Pharma and Poxel Announce Topline Results from Post-MarketingClinical Study on TWYMEEG® for the Treatment of Type 2 Diabetes in Japan DOWNLOAD Poxel press release

11 Jul 24

Theranexus – Implementation of a new equity line up to €2.5 Millions

Lyon, France, Jul 11, 2024 – Theranexus, a biopharmaceutical company innovating in the treatmentof rare neurological diseases, today publishes its cash position as of 30 June 2024, presents a progress report on Batten-1 and opens a new equity line. DOWNLOAD Theranexus press release Lyon, France – 11 juillet 2024, –…

11 Jul 24

Kalray – New financing secured up to €10 millions

Grenoble, France, Jul 11, 2024 – Kalray – KALRAY’S 2024 half revenue in line with latest announcements strong growth expected in the second half – New financing secured and confirmed outlook for expansion in AI data acceleration DOWNLOAD Kalray press release Kalray – Chiffre d’affaire semestriel conforme aux dernières annonces, forte…

14 Feb 24

New capital increase at Temisis with Société Financière Hoche Bains les Bains (SFHBB)

Vandoeuvre-lès-Nancy, France, Feb 14, 2024 – Groupe PAT – Nouvelle augmentation de capital chez Temisis avec la Société Financière Hoche Bains les Bains La Société Financière Hoche Bains les Bains , spécialisée dans la prise de participation et Plant Advanced Technologies PAT, entreprise pionnière dans la découverte et la production de…

13 Feb 24

Plant Advanced Technologies PAT is setting up an equity financing line of a maximum amount of 1 million euros with Iris.

Vandoeuvre-lès-Nancy, France, Feb 13, 2024 – Groupe PAT – Mise en place une ligne de financement en fonds propres auprès d’IRIS Plant Advanced Technologies PAT met en place une ligne de financement en fonds propres d’un montant maximum de 1 million d’euros auprès d’Iris. Groupe PAT – Establishment of an equity…

Press Release

Links